Search

Your search keyword '"Gardin, Claude"' showing total 24 results
Start Over Author "Gardin, Claude" Publication Year Range Last 3 years
24 results on '"Gardin, Claude"'

1. Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia

Author

Pardieu, Bryann, Pasanisi, Justine, Ling, Frank, Dal Bello, Reinaldo, Penneroux, Justine, Su, Angela, Joudinaud, Romane, Chat, Laureen, Wu, Hsin Chieh, Duchmann, Matthieu, Sodaro, Gaetano, Chauvel, Clémentine, Castelli, Florence A., Vasseur, Loic, Pacchiardi, Kim, Belloucif, Yannis, Laiguillon, Marie-Charlotte, Meduri, Eshwar, Vaganay, Camille, Alexe, Gabriela, Berrou, Jeannig, Benaksas, Chaima, Forget, Antoine, Braun, Thorsten, Gardin, Claude, Raffoux, Emmanuel, Clappier, Emmanuelle, Adès, Lionel, de Thé, Hugues, Fenaille, François, Huntly, Brian J., Stegmaier, Kimberly, Dombret, Hervé, Fenouille, Nina, Lobry, Camille, Puissant, Alexandre, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

2. Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Author

Duployez, Nicolas, Largeaud, Laëtitia, Duchmann, Matthieu, Kim, Rathana, Rieunier, Julie, Lambert, Juliette, Bidet, Audrey, Larcher, Lise, Lemoine, Jean, Delhommeau, François, Hirsch, Pierre, Fenwarth, Laurène, Kosmider, Olivier, Decroocq, Justine, Bouvier, Anne, Le Bris, Yannick, Ochmann, Marlène, Santagostino, Alberto, Adès, Lionel, Fenaux, Pierre, Thomas, Xavier, Micol, Jean-Baptiste, Gardin, Claude, Itzykson, Raphael, Soulier, Jean, Clappier, Emmanuelle, Recher, Christian, Preudhomme, Claude, Pigneux, Arnaud, Dombret, Hervé, Delabesse, Eric, and Sébert, Marie

Published
2022
Full Text
View/download PDF

3. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

Author

Duchmann, Matthieu, Wagner-Ballon, Orianne, Boyer, Thomas, Cheok, Meyling, Fournier, Elise, Guerin, Estelle, Fenwarth, Laurène, Badaoui, Bouchra, Freynet, Nicolas, Benayoun, Emmanuel, Lusina, Daniel, Garcia, Isabel, Gardin, Claude, Fenaux, Pierre, Pautas, Cécile, Quesnel, Bruno, Turlure, Pascal, Terré, Christine, Thomas, Xavier, Lambert, Juliette, Renneville, Aline, Preudhomme, Claude, Dombret, Hervé, Itzykson, Raphael, and Cluzeau, Thomas

Published
2022
Full Text
View/download PDF

5. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Author

Duployez, Nicolas, primary, Vasseur, Loïc, additional, Kim, Rathana, additional, Largeaud, Laëtitia, additional, Passet, Marie, additional, L’Haridon, Anaïs, additional, Lemaire, Pierre, additional, Fenwarth, Laurène, additional, Geffroy, Sandrine, additional, Helevaut, Nathalie, additional, Celli‑Lebras, Karine, additional, Adès, Lionel, additional, Lebon, Delphine, additional, Berthon, Céline, additional, Marceau-Renaut, Alice, additional, Cheok, Meyling, additional, Lambert, Juliette, additional, Récher, Christian, additional, Raffoux, Emmanuel, additional, Micol, Jean-Baptiste, additional, Pigneux, Arnaud, additional, Gardin, Claude, additional, Delabesse, Eric, additional, Soulier, Jean, additional, Hunault, Mathilde, additional, Dombret, Hervé, additional, Itzykson, Raphael, additional, Clappier, Emmanuelle, additional, and Preudhomme, Claude, additional

Published
2023
Full Text
View/download PDF

6. Abstract 464: AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles

Author

Jeammet, Louise, primary, Adicéam, Emile, additional, Habault, Justine, additional, Kaci, Anna, additional, Berrou, Jeannig, additional, Dupont, Mélanie, additional, Thonnart, Nicolas, additional, Pasquereau-Kotula, Ewa, additional, Marie-Cardine, Anne, additional, Bensussan, Armand, additional, Pla, Marika, additional, Dombret, Hervé, additional, Gardin, Claude, additional, Bagot, Martine, additional, Rain, Jean-Christophe, additional, Sicard, Hélène, additional, Tiollier, Jérôme, additional, Braun, Thorsten, additional, and Poyet, Jean-Luc, additional

Published
2023
Full Text
View/download PDF

7. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

Author

Dal Bello, Reinaldo, primary, Pacchiardi, Kim, additional, Chauvel, Clémentine, additional, Adès, Lionel, additional, Braun, Thorsten, additional, Pasanisi, Justine, additional, Fournier, Elise, additional, Berthon, Céline, additional, Clappier, Emmanuelle, additional, Raffoux, Emmanuel, additional, Lebon, Delphine, additional, Cluzeau, Thomas, additional, Roumier, Christophe, additional, Plesa, Adriana, additional, Celli-Lebras, Karine, additional, Dombret, Hervé, additional, Preudhomme, Claude, additional, Mathis, Stéphanie, additional, Puissant, Alexandre, additional, Gardin, Claude, additional, and Itzykson, Raphael, additional

Published
2022
Full Text
View/download PDF

8. Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)

Author

Berrou, Jeannig, primary, Dupont, Mélanie, additional, Djamai, Hanane, additional, Adicéam, Emilie, additional, Parietti, Véronique, additional, Kaci, Anna, additional, Clappier, Emmanuelle, additional, Cayuela, Jean-Michel, additional, Baruchel, André, additional, Paublant, Fabrice, additional, Prudent, Renaud, additional, Ghysdael, Jacques, additional, Gardin, Claude, additional, Dombret, Hervé, additional, and Braun, Thorsten, additional

Published
2022
Full Text
View/download PDF

9. Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Author

Chevallier, Patrice, primary, Leguay, Thibault, additional, KIM, Rathana, additional, Delord, Marc, additional, Doubek, Michael, additional, Huguet, Francoise, additional, Cabannes-Hamy, Aurelie, additional, Wartiovaara-Kautto, Ulla, additional, Saillard, Colombe, additional, Raffoux, Emmanuel, additional, Cluzeau, Thomas, additional, Lepretre, Stephane, additional, Balsat, Marie, additional, Berceanu, Anna, additional, Boissel, Nicolas, additional, Gardin, Claude, additional, Clappier, Emmanuelle, additional, Dombret, Herve, additional, and Rousselot, Philippe, additional

Published
2022
Full Text
View/download PDF

10. Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

Author

Fenwarth, Laurène, primary, Vasseur, Loïc, additional, Duployez, Nicolas, additional, Gardin, Claude, additional, Terré, Christine, additional, Lambert, Juliette, additional, de Botton, Stéphane, additional, Celli-Lebras, Karine, additional, Turlure, Pascal, additional, Cluzeau, Thomas, additional, Braun, Thorsten, additional, Thomas, Xavier, additional, Recher, Christian, additional, Chantepie, Sylvain, additional, Pautas, Cécile, additional, Dombret, Hervé, additional, Preudhomme, Claude, additional, and Itzykson, Raphael, additional

Published
2022
Full Text
View/download PDF

11. UBTFtandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Author

Duployez, Nicolas, Vasseur, Loïc, Kim, Rathana, Largeaud, Laëtitia, Passet, Marie, L’Haridon, Anaïs, Lemaire, Pierre, Fenwarth, Laurène, Geffroy, Sandrine, Helevaut, Nathalie, Celli‑Lebras, Karine, Adès, Lionel, Lebon, Delphine, Berthon, Céline, Marceau-Renaut, Alice, Cheok, Meyling, Lambert, Juliette, Récher, Christian, Raffoux, Emmanuel, Micol, Jean-Baptiste, Pigneux, Arnaud, Gardin, Claude, Delabesse, Eric, Soulier, Jean, Hunault, Mathilde, Dombret, Hervé, Itzykson, Raphael, Clappier, Emmanuelle, and Preudhomme, Claude

Abstract

Tandem duplications (TDs) of the UBTFgene have been recently described as a recurrent alteration in pediatric acute myeloid leukemia (AML). Here, by screening 1946 newly diagnosed adult AML, we found that UBTF-TDs occur in about 3% of patients aged 18–60 years, in a mutually exclusive pattern with other known AML subtype-defining alterations. The characteristics of 59 adults with UBTF-TD AML included young age (median 37 years), low bone marrow (BM) blast infiltration (median 25%), and high rates of WT1mutations (61%), FLT3-ITDs (51%) and trisomy 8 (29%). BM morphology frequently demonstrates dysmyelopoiesis albeit modulated by the co-occurrence of FLT3-ITD. UBTF-TD patients have lower complete remission (CR) rates (57% after 1 course and 76% after 2 courses of intensive chemotherapy [ICT]) than UBTF-wild-type patients. In patients enrolled in the ALFA-0702 study (n= 614 patients including 21 with UBTF-TD AML), the 3-year disease-free survival (DFS) and overall survival of UBTF-TD patients were 42.9% (95%CI: 23.4–78.5%) and 57.1% (95%CI: 39.5–82.8%) and did not significantly differ from those of ELN 2022 intermediate/adverse risk patients. Finally, the study of paired diagnosis and relapsed/refractory AML samples suggests that WT1-mutated clones are frequently selected under ICT. This study supports the recognition of UBTF-TD AML as a new AML entity in adults.

Published
2023
Full Text
View/download PDF

12. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)

Author

Djamai, Hanane, primary, Berrou, Jeannig, additional, Dupont, Mélanie, additional, Coudé, Marie-Magdelaine, additional, Delord, Marc, additional, Clappier, Emmanuelle, additional, Marceau-Renaut, Alice, additional, Kaci, Anna, additional, Raffoux, Emmanuel, additional, Itzykson, Raphaël, additional, Berthier, Caroline, additional, Wu, Hsin-Chieh, additional, Hleihel, Rita, additional, Bazarbachi, Ali, additional, de Thé, Hugues, additional, Baruchel, André, additional, Gardin, Claude, additional, Dombret, Hervé, additional, and Braun, Thorsten, additional

Published
2021
Full Text
View/download PDF

13. Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study

Author

Chevallier, Patrice, primary, Leguay, Thibault, additional, Doubek, Michael, additional, Huguet, Francoise, additional, Salek, Cyril, additional, Cabannes, Aurélie, additional, Wartiovaara-Kautto, Ulla, additional, Saillard, Colombe, additional, Raffoux, Emmanuel, additional, Cluzeau, Thomas, additional, Leprêtre, Stéphane, additional, Balsat, Marie, additional, Berceanu, Anna, additional, Boissel, Nicolas, additional, Clappier, Emmanuelle, additional, Morisset, Laure, additional, Gardin, Claude, additional, Dombret, Hervé, additional, and Rousselot, Philippe, additional

Published
2021
Full Text
View/download PDF

14. Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

Author

Lambert, Juliette, primary, Lambert, Jérôme, additional, Lemasle, Emilie, additional, Joris, Magalie, additional, Chantepie, Sylvain, additional, Pautas, Cecile, additional, Thomas, Xavier, additional, Malfuson, Jean Valere, additional, Gastaud, Lauris, additional, Caillot, Denis, additional, Tavernier, Emmanuelle, additional, Turlure, Pascal, additional, Carp, Diana, additional, Berthon, Celine, additional, Legrand, Olivier, additional, Marçais, Ambroise, additional, Vaida, Iona, additional, Barbieux, Sarah, additional, Rousselot, Philippe, additional, Gardin, Claude, additional, Terré, Christine, additional, Duployez, Nicolas, additional, Preudhomme, Claude, additional, Celli-Lebras, Karine, additional, Castaigne, Sylvie, additional, and Dombret, Herve, additional

Published
2021
Full Text
View/download PDF

15. Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Author

Duployez, Nicolas, primary, Duchmann, Matthieu, additional, Largeaud, Laetitia, additional, Lambert, Juliette, additional, Bidet, Audrey, additional, Clappier, Emmanuelle, additional, Thomas, Xavier, additional, de Botton, Stephane, additional, Gardin, Claude, additional, Recher, Christian, additional, Pigneux, Arnaud, additional, Itzykson, Raphael, additional, Preudhomme, Claude, additional, Dombret, Hervé, additional, Delabesse, Eric, additional, and Sebert, Marie, additional

Published
2021
Full Text
View/download PDF

16. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

Author

Duchmann, Matthieu, primary, Wagner-Ballon, Orianne, additional, Boyer, Thomas, additional, Cheok, Meyling, additional, Fournier, Elise, additional, Guerin, Estelle, additional, Fenwarth, Laurène, additional, Badaoui, Bouchra, additional, Freynet, Nicolas, additional, Benayoun, Emmanuel, additional, Lusina, Daniel, additional, Garcia, Isabel, additional, Gardin, Claude, additional, Fenaux, Pierre, additional, Pautas, Cécile, additional, Quesnel, Bruno, additional, Turlure, Pascal, additional, Terré, Christine, additional, Thomas, Xavier, additional, Lambert, Juliette, additional, Renneville, Aline, additional, Preudhomme, Claude, additional, Dombret, Hervé, additional, Itzykson, Raphael, additional, and Cluzeau, Thomas, additional

Published
2021
Full Text
View/download PDF

17. Prognostic impact of DDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study

Author

Duployez, Nicolas, Largeaud, Laëtitia, Duchmann, Matthieu, Kim, Rathana, Rieunier, Julie, Lambert, Juliette, Bidet, Audrey, Larcher, Lise, Lemoine, Jean, Delhommeau, François, Hirsch, Pierre, Fenwarth, Laurène, Kosmider, Olivier, Decroocq, Justine, Bouvier, Anne, Le Bris, Yannick, Ochmann, Marlène, Santagostino, Alberto, Adès, Lionel, Fenaux, Pierre, Thomas, Xavier, Micol, Jean-Baptiste, Gardin, Claude, Itzykson, Raphael, Soulier, Jean, Clappier, Emmanuelle, Recher, Christian, Preudhomme, Claude, Pigneux, Arnaud, Dombret, Hervé, Delabesse, Eric, and Sébert, Marie

Abstract

DDX41germline mutations (DDX41MutGL) are the most common genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia (AML). Recent reports suggest that DDX41MutGLmyeloid malignancies could be considered as a distinct entity, even if their specific presentation and outcome remain to be defined. We described here the clinical and biological features of 191 patients with DDX41MutGLAML. Baseline characteristics and outcome of 86 of them, treated with intensive chemotherapy in 5 prospective ALFA/FILO trials were compared with those of 1604 DDX41wild-type (DDX41WT) AML patients, representing a prevalence of 5%. DDX41MutGLAML patients were mostly males (75%) in their seventh decade, with low leukocyte count (median, 2x109/L), low bone marrow blast infiltration (median, 33%), normal cytogenetics (75%) and few additional somatic mutations (median, 2). A second somatic DDX41mutation (DDX41MutSom) was found in 82% of patients and clonal architecture inference suggested that it could be the main driver for AML progression. DDX41MutGLpatients displayed higher complete remission (CR) rates (94% vs.69%, p<0.0001) and longer restricted mean overall survival (OS) censored at hematopoietic stem cell transplantation (HSCT) than ELN-2017 intermediate/adverse (Int/Adv) DDX41WTpatients (5-year ΔRMST of 13.6 months, p < 0.001). Relapse rates censored at HSCT were lower at 1 year in DDX41MutGLpatients (15% vs.44%) but later increased to join that of Int/Adv DDX41WTpatients at 3 years (82% vs 75%). HSCT in first CR was associated with prolonged relapse-free survival (RFS; HR, 0.43 [95%CI, 0.21-0.88]; p = 0.02) but not with longer OS (HR=0.77 [95%CI, 0.35-1.68], p=0.5).

Published
2024
Full Text
View/download PDF

18. Treatment of Adverse-Risk and Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients with FLAG-IDA ± Venetoclax and CLAG-M: A Monocentric Experience

Author

Rahmé, Ramy, Vidal, Valérie, Hueso, Thomas, Le Meur, Lucie, Rigal, Marthe, Ivanoff, Sarah, Brechignac, Sabine, Peffault De Latour, Regis, Gardin, Claude, and Braun, Thorsten

Abstract

Background:ELN 2022 risk classification of AML includes three risk categories and guides treatment choice. Adverse-risk patients, encompassing secondary (sAML) and therapy-related AML (tAML), show lower response rates to upfront traditional intensive chemotherapy (IC) combining anthracycline and cytarabine (3+7 regimen). In refractory/relapsed (R/R) cases, no standard IC approach is established, in particular as a bridging therapy to allogeneic stem cell transplantation (ASCT) that, whenever feasible, remains the only curative strategy. Recently, alternative IC such as CLAG-M (cladribine, cytarabine, G-CSF and mitoxantrone) and FLAG-IDA (fludarabine, cytarabine, G-CSF and idarubicin) were considered for adverse-risk and R/R patients, and were associated with encouraging results including our recent experience with CLAG-M. Specifically, the addition of the bcl2 inhibitor venetoclax (VEN) to FLAG-IDA was associated with deep remissions and a high rate of transition to transplantation (56%). As publications on intensive approaches in these high-risk patients remain sparse in the literature, we report our single-center experience with FLAG-IDA ± VEN compared to our updated experience with CLAG-M in this setting.

Published
2023
Full Text
View/download PDF

19. Hyperleukocytosis Increases the Risk of Early Relapses Independently of Genetics in AML

Author

Liévin, Raphaël, Duployez, Nicolas, Vasseur, Loïc, Lambert, Juliette, Heiblig, Mael, Hunault, Mathilde, Gardin, Claude, De Botton, Stephane, Fournier, Elise, Pautas, Cecile, Terré, Christine, Delabesse, Eric, Ifrah, Norbert, Pigneux, Arnaud, Karine, Celli-Lebras, Recher, Christian, Preudhomme, Claude, Dombret, Herve, and Itzykson, Raphael

Abstract

Background. Higher white blood cell (WBC) count at diagnosis is associated with specific gene lesions and higher early death rates in AML patients (pts) treated intensively. Whether higher WBC count at diagnosis affects outcome beyond remission independently of genetics is unknown.

Published
2023
Full Text
View/download PDF

20. Venetoclax in Combination with Intermediate Doses of Cytarabine in Consolidation Phase for Acute Myeloid Leukemia Patients in First Complete Remission; Results of the Part 1 of the Phase 1/2 Multicentric Covenidac Study

Author

Gastaud, Lauris, Peterlin, Pierre, Hunault, Mathilde, Raffoux, Emmanuel, Bertoli, Sarah, Carré, Martin, Pautas, Cecile, Chantepie, Sylvain, Lambert, Juliette, Duployez, Nicolas, Celli-Lebras, Karine, Mineur, Ariane, Gardin, Claude, Vey, Norbert, Pigneux, Arnaud, Delabesse, Eric, Preudhomme, Claude, Plesa, Adriana, Vergez, Francois, Hamel, Jean-François, Dombret, Herve, and Recher, Christian

Abstract

For authors: Please: L Gastaud and P Peterlin: co-primary, H dombret et C Recher: co-last

Published
2023
Full Text
View/download PDF

21. Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Author

Mathilde, Hunault-Berger, Pautas, Cécile, Bertoli, Sarah, Dumas, Pierre-Yves, Raffoux, Emmanuel, Marchand, Tony, Hospital, Marie Anne, Heiblig, Mael, Chantepie, Sylvain, Carré, Martin, Peterlin, Pierre, Lemasle, Emilie, Simand, Célestine, Gallego Hernanz, Maria Pilar, Huynh, Anne, Forcade, Edouard, Devillier, Raynier, Nguyen Quoc, Stéphanie, Duployez, Nicolas, Luquet, Isabelle, Penther, Dominique, Celli-Lebras, Karine, Mineur, Ariane, Gardin, Claude, Socié, Gerard, Cahn, Jean-Yves, Ifrah, Norbert, Vey, Norbert, Peffault De Latour, Regis, Delabesse, Eric, Preudhomme, Claude, Hamel, Jean-François, Pigneux, Arnaud, Recher, Christian, and Dombret, Hervé

Abstract

Introduction. This multicenter study randomly explored various standard intensive chemotherapy (ICT) strategies in adults with AML, namely higher-dose idarubicin (IDA) vshigh-dose daunorubicin (DNR) and intermediate-dose (IDAC) vshigh-dose (HDAC) cytarabine. The study was planned large enough to allow patient subgroup analysis.

Published
2023
Full Text
View/download PDF

22. Prognostic Impact of Monoallelic Versus Biallelic TP53Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

Author

Fenwarth, Laurène, Vasseur, Loïc, Duployez, Nicolas, Gardin, Claude, Terré, Christine, Lambert, Juliette, de Botton, Stéphane, Celli-Lebras, Karine, Turlure, Pascal, Cluzeau, Thomas, Braun, Thorsten, Thomas, Xavier, Recher, Christian, Chantepie, Sylvain, Pautas, Cécile, Dombret, Hervé, Preudhomme, Claude, and Itzykson, Raphael

Published
2022
Full Text
View/download PDF

23. Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively.

Author

Dal Bello, Reinaldo, Pacchiardi, Kim, Chauvel, Clémentine, Adès, Lionel, Braun, Thorsten, Pasanisi, Justine, Fournier, Elise, Berthon, Céline, Clappier, Emmanuelle, Raffoux, Emmanuel, Lebon, Delphine, Cluzeau, Thomas, Roumier, Christophe, Plesa, Adriana, Celli-Lebras, Karine, Dombret, Hervé, Preudhomme, Claude, Mathis, Stéphanie, Puissant, Alexandre, and Gardin, Claude

Published
2023
Full Text
View/download PDF

24. Prognostic Significance of DDX41Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study

Author

Duployez, Nicolas, Duchmann, Matthieu, Largeaud, Laetitia, Lambert, Juliette, Bidet, Audrey, Clappier, Emmanuelle, Thomas, Xavier, de Botton, Stephane, Gardin, Claude, Recher, Christian, Pigneux, Arnaud, Itzykson, Raphael, Preudhomme, Claude, Dombret, Hervé, Delabesse, Eric, and Sebert, Marie

Abstract

Background:The WHO 2016 classification identifies myeloid malignancies with germline predisposition as a distinct subgroup (Arber DA et al., Blood 2016). We and other reported mutations of the DEAD-box RNA helicase 41 gene (g DDX41m) as the most common predisposition to MDS/AML (Sébert et al., Blood 2019). Relatively good outcomes have been suggested in small cohorts receiving heterogeneous treatment, but the prognostic significance of g DDX41m in AML patients (pts) treated with intensive chemotherapy (IC) has never been reported. Here, we analyzed the prognostic impact of g DDX41m in a large cohort of newly diagnosed AML pts treated with IC in 5 prospective ALFA (Acute Leukemia French Association) and FILO (French Innovative Leukemia Organization) trials.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results